Seeking Alpha

Celgene (CELG +0.5%) shrugs off a valuation downgrade by Jefferies earlier today to finish...

Celgene (CELG +0.5%) shrugs off a valuation downgrade by Jefferies earlier today to finish higher. The stock took a beating yesterday on the back of a negative report by the European Medicines Agency regarding CELG's withdrawal of its application for an expansion of its multiple myeloma treatment Revlimid. Investors are discouraged by the report's lack of a clear path toward gaining approval.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|